Trial Profile
Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; T cell replacement therapy (Primary) ; Cytarabine; Dexamethasone; Methotrexate
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms DLI-TARGET
- 07 Mar 2024 Status changed from recruiting to withdrawn prior to enrolment.
- 20 Jul 2020 This trial is discontinued (Global End Date: 06 Jul 2020), according to European Clinical Trials Database record.
- 27 Aug 2018 New trial record